Grants and Contributions:
Title:
Support for critical release assays for GMP-grade CD22-single domain antibody based CAR lentiviral product
Agreement Number:
986038
Agreement Value:
$217,937.00
Agreement Date:
Jan 25, 2022 - Oct 31, 2023
Description:
This project will support the development, validation, qualification and execution of a number of release assays critical to the release of the GMP lentiviral vector that will be used to generate a next generation CAR-T cell product (CD22) to be tested in a clinical trial extending across Canada. Manufacturing of the lentiviral product is scheduled to start February 2022.
Organization:
National Research Council Canada
Expected Results:
In the short term, anticipated outcomes will be strengthened collaborations across industry, academia, and government to support research excellence. In the medium term, anticipated outcomes will be the development of new and potentially disruptive technologies with collaborators. In the long term, find collaborative solutions to public policy challenges and create stronger innovation systems.
Location:
Ottawa, Ontario, CA K1H 8L6
Reference Number:
172-2021-2022-Q1-986038
Agreement Type:
Contribution
Report Type:
Grants and Contributions
Recipient Business Number:
886822212
Recipient Type:
Not-for-profit organization or charity
Additional Information:
This agreement has been amended 2 time. The end date of this agreements has been modified by 389 days
Amendment Date
Mar 31, 2023
Recipient's Legal Name:
Ottawa Hospital Research Institute
Federal Riding Name:
Ottawa South
Federal Riding Number:
35077
Program:
Collaborative Science, Technology and Innovation Program - Collaborative R&D Initiatives
Program Purpose:
Collaborate on multiparty research and development programs to catalyze transformative, high-risk, high-reward research with the potential for game-changing scientific discoveries and technological breakthroughs in priority areas.
NAICS Code:
541710
Amendments: